Dr. Georg Winter explores how chemical neomorphs can give proteins new functions by reshaping their cellular interactions, ...
Cancer immunology is advancing rapidly as researchers seek to unravel the complex, dynamic relationships between tumor cells, immune populations, and the ...
The role of neural hearing loss (NHL) in development of hearing impairment is increasingly recognised by the clinical community as central to hearing loss. NHL represents a significant unmet medical ...
Kelonia is developing a next-gen blood cancer treatment that’ll reprogram T-cells to help patients’ immune systems fight ...
Tumor-associated macrophages (TAMs) within the tumor microenvironment (TME) exhibit significant metabolic dysregulation, ...
Discusses Intracranial Activity of a New Therapy in Small Cell Lung Cancer With Brain Metastases April 20, 2026 8:30 AM ...
By enrolling the world's first participant, the Sarah Cannon Transplant & Cellular Therapy Program at St. David's South Austin Medical Center made this therapy available to patients before it was ...
Investor's Business Daily on MSN
Eli Lilly snags $7 billion cancer deal to rival Gilead, J&J, others
Eli Lilly said Monday it will spend up to $7 billion to buy privately held Kelonia Therapeutics for its suite of cancer treatments.
Worth up to $7 billion, Lilly’s second recent acquisition of a company in the space is centered around a cell therapy that’s ...
Objective Macrophages and kidney cell pyroptosis/ferroptosis could play an important role in the pathogenesis of lupus ...
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products, today announced upcoming presentations at the ...
Therapeutic fasting offers a metabolic approach to chronic pain by shifting to fat metabolism, reducing systemic inflammation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results